WIN-x Synthetic Cannabinoids Cannabinoid Research

WIN-x Synthetic Cannabinoids Research Dashboard

85

Primary Studies

48

Related Studies

133

Total Studies

Clinical Studies

0

Double-blind human trials

1

Clinical human trials

Pre-Clinical Studies

1

Meta-analyses/Reviews

58

Animal studies

25

Laboratory studies

What am I missing as a non-subscriber?

To see a full dashboard with study details and filtering, go to our DEMO page.

As a subscriber, you will be able to access dashboard insights including chemotype overviews and dosing summaries for medical conditions and organ system and receptor breakdowns for cannabinoid and terpene searches. Study lists present important guidance including dosing and chemotype information with the ability to drill down to the published material. And all outputs are fully filterable, to help find just the information you need. Stay up-to-date with the science of cannabis and the endocannabinoid system with CannaKeys.

CannaKeys has 133 studies associated with WIN-x Synthetic Cannabinoids.

Here is a small sampling of WIN-x Synthetic Cannabinoids studies by title:


Components of the WIN-x Synthetic Cannabinoids Research Dashboard

  • Top medical conditions associated with WIN-x Synthetic Cannabinoids
  • Proven effects in clinical trials for WIN-x Synthetic Cannabinoids
  • Receptors associated with WIN-x Synthetic Cannabinoids
  • Individual study details for WIN-x Synthetic Cannabinoids

Ready to become a subscriber? Go to our PRICING page.

Select New Cannabinoid

Filter Cannabinoid

Members can filter by the following criteria:

  • Study Type
  • Organ Systems
  • Terpenes
  • Receptors
  • Ligands
  • Study Result
  • Year of Publication

Overview - WIN-x Synthetic Cannabinoids

Description of WIN-x Synthetic Cannabinoids

Compounds in this family are synthetic exogenous cannabinoid receptor agonists. An example is WIN-55,212-2.

Other Names:

WIN Family Synthetic Cannabinoids

WIN-x Synthetic Cannabinoids Properties and Effects

Reduces inflammatory pain via TRPA1, Initiates anti-inflammatory responses via PPAR-y

WIN-x Synthetic Cannabinoids Receptor Binding

Moderate affinity for CB1 with a mean Kd 16.7nM (1.5 times more potent than THC). Strong affinity for CB2 with a mean Kd 3.7nM (9.5 times more potent than THC). Binds with TRPA1. Binds with PPAR-y.

Disclaimers: Information on this site is provided for informational purposes only and is not meant to substitute for the advice provided by your own physician or other medical professional. You should not use the information contained herein for diagnosing a health problem or disease. If using a product, you should read carefully all product packaging. If you have or suspect that you have a medical problem, promptly contact your health care provider.

Information on this site is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over-the-counter medication is also available. Consult your physician, nutritionally oriented health care practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications.